Mesoblast Limited (ASX:MSB) Key Patents Granted In United States Strengthen Commercial Rights And Broaden Clinical Indications
Mesoblast Limited (ASX:MSB) Key Patents Granted In United States Strengthen Commercial Rights And Broaden Clinical Indications
Melbourne, May 24, 2011 AEST (ABN Newswire) - Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that the company's product development strategy has been significantly strengthened by novel composition of matter claims granted by the United States Patent and Trade Mark Office (USPTO) in two distinct patent families to which Mesoblast has exclusive worldwide commercial rights.

Together with earlier composition of matter claims in US patent 7,122,178 relating to Mesoblast's proprietary Mesenchymal Precursor Cell (MPCs) technology platform, these new US patents 7,052,907 and 7,947,266 give Mesoblast exclusive ownership over MPCs derived from a variety of sources, including dental pulp and adipose tissue (fat), in addition to bone marrow.

The MPCs derived from dental pulp may be particularly effective for the treatment and prevention of neural degenerative diseases such as Parkinson's disease and Alzheimer's disease, as well as for dental applications such as regenerating teeth. Adipose-derived MPCs may have particular benefits for reconstructive surgery and cosmetic indications.

The new granted US patents extend Mesoblast's ownership of MPCs through to 2025, and ensure that during this period only Mesoblast can commercialize MPC products in the United States, the world's largest healthcare market.

Beyond that period, under the United States Patient Protection and Affordable Care Act enacted in 2010, Mesoblast may be entitled to further exclusive commercial protection for the company's biologic products in the United States.

Mesoblast Chief Executive, Professor Silviu Itescu, said the new patents are major assets that confer certainty, broaden the range of product offerings by the company, and significantly increase the commercial value of the platform technology.

"Maintaining commercial exclusivity for our adult stem cell products through a robust international patent portfolio is fundamental to our commercial strategy," Professor Itescu added.

About Mesoblast Limited

Mesoblast Limited (ASX:MSB) (OTC ADR: MBLTY) is the world's leading developer of innovative biological products for the broad field of regenerative medicine.

Mesoblast's commercial strategy is based on its unique proprietary adult mesenchymal precursor cells.

The company's lead products will target cardiovascular conditions, diabetes, inflammatory conditions of lungs and joints, eye diseases, bone marrow cancers, bone fractures, cartilage degeneration and musculoskeletal conditions.

Mesoblast and global biopharmaceutical company Cephalon Inc. have established a strategic alliance to commercialize adult stem cell products for degenerative conditions of the cardiovascular and central nervous systems. The alliance also extends to products for augmenting bone marrow transplantation in cancer patients.



Julie Meldrum
Corporate Communications Director
T: +61-3-9639-6036

Related Companies

Mesoblast Limited       

ABN Newswire This Page Viewed:  (Last 7 Days: 3) (Last 30 Days: 11) (Since Published: 3530) 

Mesoblast Limited NEWS: RECENT VISITS (1367)